Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B

Table 5 Predictors associated with occurrence of HCC after treatment in patients with HBV infection

Factors	Group	Univariate analysis			Multivariable analysis
		Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value
Age, years	≥ 60 VS < 60	4.41	1.88–10.32	0.001	1.13	0.29–4.43	0.87
Sex	Male VS Female	1.30	0.49–3.50	0.60
SWE, kPa		1.09	1.06–1.12	< 0.001	1.07	1.02–1.12	0.01
AFP in Baseline		1.02	0.98–1.04	0.45
PLT, 10^9/L	< 100 VS ≥ 100	2.15	0.95–4.84	0.07
Log10 HBVDNA		1.10	0.92–1.32	0.30
HBeAg( +)	Positive VS Negative	0.96	0.43–2.14	0.92
Log10 HBsAg, IU/mL		0.69	0.55–1.03	0.11
REACH-B score		1.32	1.17–1.50	< 0.001	1.12	0.95–1.32	0.18
Page-B score		1.18	1.08–1.29	< 0.001	0.95	0.77–1.18	0.64
mPage-B score		1.29	1.16–1.43	< 0.001	1.19	0.78–1.79	0.42
aMAP score		1.12	1.06–1.17	< 0.001	1.01	0.86–1.18	0.94
NAFLD	Yes VS No	0.48	0.11–2.06	0.33
T2DM	Yes VS No	4.21	1.25–14.17	0.02	0.63	0.11–3.69	0.61
Nucleoside analogues	ETV VS TDF	6.90	0.92–51.68	0.06

HCC hepatic cell carcinoma, HBV hepatitis B virus, SWE shear wave elastography, AFP alpha fetoprotein, PLT platelet, NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, ETV entecavir, TDF tenofovir disoproxil fumarate

ISSN: 1750-9378